Avanos CFO awarded stock options and RSUs

Avanos Medical SVP and CFO Scott Michael Galovan reported equity awards as part of his compensation.

Rhea-AI Filing Summary

Avanos Medical SVP and CFO Scott Michael Galovan reported equity awards as part of his compensation. He received an employee stock option grant for 69,630 shares of Common Stock at an exercise price of $13.69 per share, expiring on March 13, 2036.

He was also granted 29,481 time-based restricted share units, each economically equivalent to one share of Common Stock. These RSUs vest in three equal installments on March 13, 2027, March 13, 2028, and March 13, 2029. Following the grants, he holds 139,824 shares of Common Stock directly and 96,212 options.

Insider Trade Summary

Grant/Award: 99,111 shares

Grant/Award 2 txns

Insider Galovan Scott Michael

Role SVP, Chief Financial Officer

Type	Security	Shares	Price	Value
Grant/Award	Employee Stock Option (right to buy)	69,630	$0.00	$0.00
Grant/Award	Common Stock	29,481	$0.00	$0.00

Holdings After Transaction: Employee Stock Option (right to buy) — 96,212 contracts (Direct); Common Stock — 139,824 shares (Direct)

Footnotes (2)

1. F1. Represents time-based restricted share units (TRSUs) awarded pursuant to the Issuer's 2021 Long Term Incentive Plan, as amended. The award will vest 1/3 on March 13, 2027, 1/3 on March 13, 2028 and 1/3 on March 13, 2029. Each TRSU is the economic equivalent of one share of Common Stock.
2. F2. The award will vest 30% on March 13, 2027, 30% on March 13, 2028 and 40% on March 13, 2029.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What equity awards did Avanos Medical (AVNS) CFO Scott Galovan receive?

Scott Galovan received a stock option grant for 69,630 shares at an exercise price of $13.69 and 29,481 time-based restricted share units. These awards form part of his long-term incentive compensation at Avanos Medical.

How do the new stock options for Avanos (AVNS) CFO Scott Galovan work?

The stock options cover 69,630 shares of Avanos Common Stock with an exercise price of $13.69 per share and an expiration date of March 13, 2036. Galovan must pay the exercise price to convert options into shares in the future.

When will the restricted share units granted to Avanos (AVNS) CFO vest?

The 29,481 time-based restricted share units vest in three equal installments on March 13, 2027, March 13, 2028, and March 13, 2029. Each vested unit delivers the economic equivalent of one Avanos Common Stock share.

How many Avanos (AVNS) shares does CFO Scott Galovan hold after these awards?

After the reported awards, Scott Galovan directly holds 139,824 shares of Avanos Common Stock. He also holds 96,212 stock options, reflecting his ongoing equity-based alignment with Avanos Medical’s shareholder value over the long term.

Are the Avanos (AVNS) CFO’s new awards open-market purchases or grants?

The Form 4 shows grant or award acquisitions, not open-market purchases. Both the 69,630 stock options and 29,481 restricted share units were issued at no cash cost to the CFO as part of Avanos Medical’s long-term incentive plan.

What incentive plan governs the Avanos (AVNS) CFO’s restricted share units?

The time-based restricted share units were granted under Avanos Medical’s 2021 Long Term Incentive Plan, as amended. This plan provides equity awards that vest over several years, linking executive compensation to the company’s long-term performance and retention goals.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/17/2026 - 05:25 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Galovan Scott Michael

(Last) (First) (Middle)

5405 WINDWARD PARKWAY

SUITE 100

(Street)

ALPHARETTA GA 30004

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
AVANOS MEDICAL, INC. [ AVNS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP, Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/13/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/13/2026		A		29,481(1)	A	$0	139,824	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (right to buy)	$13.69	03/13/2026		A		69,630		(2)	03/13/2036	Common Stock	69,630	$0	96,212	D

Explanation of Responses:

1. Represents time-based restricted share units (TRSUs) awarded pursuant to the Issuer's 2021 Long Term Incentive Plan, as amended. The award will vest 1/3 on March 13, 2027, 1/3 on March 13, 2028 and 1/3 on March 13, 2029. Each TRSU is the economic equivalent of one share of Common Stock.

2. The award will vest 30% on March 13, 2027, 30% on March 13, 2028 and 40% on March 13, 2029.

Remarks:

	/s/ John Hurley, as attorney-in-fact for Scott M. Galovan	03/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.